Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 17 of 18
Next
>>
>
401 to 425 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC70	XL147	1	72	flat	flat	HCC70 pilaralisib 0 1 72	8	1.396	Inf	1.05	-0.0406	0.0	1.05	0.01	-0.285	1.0	1.03	Inf	1.04	1.03	0.0	1.04	0.01	-0.295	1.0	1.02
BT-549	XL147	3	72	flat	flat	BT549 pilaralisib 0 3 72	8	1.772	Inf	0.933	0.0351	0.0	0.933	0.01	-0.0699	1.0	0.962	Inf	0.941	0.969	0.0	0.941	0.01	-0.0712	1.0	0.967
BT-549	XL147	2	72	flat	flat	BT549 pilaralisib 0 2 72	8	1.952	Inf	0.967	-0.00824	0.0	0.967	0.01	-0.000427	1.0	1.0	Inf	0.968	1.01	0.0	0.968	0.01	-0.000878	1.0	1.0
BT-549	XL147	1	72	flat	flat	BT549 pilaralisib 0 1 72	8	1.855	Inf	0.941	0.0385	0.0	0.941	0.01	-0.0931	1.0	0.954	Inf	0.946	0.965	0.0	0.946	0.01	-0.0808	1.0	0.958
HCC1806	XL147	3	72	flat	flat	HCC1806 pilaralisib 0 3 72	8	3.185	Inf	1.02	0.000871	0.0	1.02	0.01	-2.12e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000107	1.0	1.0
HCC1806	XL147	2	72	flat	flat	HCC1806 pilaralisib 0 2 72	8	2.817	Inf	1.02	0.000975	0.0	1.02	0.01	-4.46e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000109	1.0	1.0
HCC1806	XL147	1	72	flat	flat	HCC1806 pilaralisib 0 1 72	8	2.732	Inf	1.02	0.00101	0.0	1.02	0.01	-4.53e-06	1.0	1.0	Inf	1.03	0.999	0.0	1.03	0.01	-0.000107	1.0	1.0
Hs 578T	XL147	3		flat	flat	Hs578T pilaralisib 3	8	2.879	Inf	0.971	-0.00618	0.0	0.971	0.01	0.331	0.299	1.0	Inf	0.959	1.01	0.0	0.959	0.01	0.319	0.315	1.0
Hs 578T	XL147	2		flat	flat	Hs578T pilaralisib 2	8	2.509	Inf	0.976	0.000255	0.0	0.976	0.01	0.435	0.181	0.997	Inf	0.97	1.0	0.0	0.97	0.01	0.432	0.183	0.996
Hs 578T	XL147	1		flat	flat	Hs578T pilaralisib 1	8	2.013	Inf	0.967	0.00411	0.0	0.967	0.01	0.193	0.525	0.991	Inf	0.967	0.996	0.0	0.967	0.01	0.196	0.519	0.991
BT-20	XL147	1	72	flat	flat	BT20 pilaralisib 0 1 72	8	2.128	Inf	0.815	0.048	0.0	0.815	0.01	0.411	0.205	0.939	Inf	0.813	0.95	0.0	0.813	0.01	0.383	0.234	0.937
BT-20	XL147	2	72	flat	flat	BT20 pilaralisib 0 2 72	8	1.784	Inf	0.759	0.073	0.0	0.759	0.01	-0.0058	1.0	0.907	Inf	0.796	0.937	0.0	0.796	0.01	-0.00637	1.0	0.92
BT-20	XL147	3	72	flat	flat	BT20 pilaralisib 0 3 72	8	2.647	Inf	0.755	0.102	0.0	0.755	0.01	0.0679	0.81	0.885	Inf	0.708	0.871	0.0	0.708	0.01	0.0505	0.856	0.857
HCC38	XL147	3	72	sigmoid	sigmoid	HCC38 pilaralisib 0 3 72	8	1.420	Inf	0.909	0.0219	0.114	0.921	5.0	0.815	0.00631	NA	Inf	0.936	0.985	0.114	0.945	5.0	0.813	0.00654	NA
HCC70	ZSTK474	3	72	sigmoid	sigmoid	HCC70 ZSTK474 0 3 72	8	2.502	0.455	0.176	0.223	0.345	0.155	1.35	0.991	8.07e-07	NA	0.401	0.265	0.782	0.24	0.274	1.55	0.987	1.99e-06	NA
Hs 578T	ZSTK474	2		sigmoid	sigmoid	Hs578T ZSTK474 2	8	2.554	0.715	0.187	0.263	5.92	-0.896	0.485	0.995	1.27e-07	NA	0.583	0.264	0.722	0.583	0.0	0.56	0.993	3.28e-07	NA
Hs 578T	ZSTK474	3		sigmoid	sigmoid	Hs578T ZSTK474 3	8	2.863	0.913	0.31	0.201	0.613	0.143	0.846	0.999	6.21e-10	NA	0.607	0.298	0.767	0.329	0.211	0.895	0.999	1.43e-09	NA
HCC70	ZSTK474	2	72	sigmoid	sigmoid	HCC70 ZSTK474 0 2 72	8	1.737	0.248	-0.0397	0.324	0.27	-0.0591	1.33	0.992	5.33e-07	NA	0.379	0.28	0.76	0.214	0.28	1.43	0.989	1.22e-06	NA
HCC70	ZSTK474	1	72	sigmoid	sigmoid	HCC70 ZSTK474 0 1 72	8	1.332	0.167	-0.265	0.366	0.201	-0.206	1.85	0.975	1.56e-05	NA	0.289	0.264	0.782	0.182	0.299	1.96	0.971	2.35e-05	NA
HCC38	ZSTK474	3	72	sigmoid	sigmoid	HCC38 ZSTK474 0 3 72	8	1.458	2.06	0.398	0.146	5.06	-0.41	0.665	0.989	1.23e-06	NA	6.44	0.593	0.898	3.35	0.179	0.678	0.988	1.64e-06	NA
HCC38	ZSTK474	2	72	sigmoid	sigmoid	HCC38 ZSTK474 0 2 72	8	2.253	1.63	0.396	0.196	2.18	-0.0865	0.554	0.984	4.3e-06	NA	2.0	0.445	0.803	1.14	0.135	0.556	0.982	5.91e-06	NA
BT-549	ZSTK474	3	72	sigmoid	sigmoid	BT549 ZSTK474 0 3 72	8	1.776	0.504	0.139	0.267	0.616	-0.0912	0.836	0.996	7.06e-08	NA	0.994	0.368	0.789	0.489	0.218	0.808	0.995	9.19e-08	NA
BT-549	ZSTK474	2	72	sigmoid	sigmoid	BT549 ZSTK474 0 2 72	8	1.962	0.628	0.144	0.245	0.841	-0.139	0.84	0.995	1.29e-07	NA	0.958	0.334	0.791	0.595	0.163	0.828	0.992	4.28e-07	NA
BT-549	ZSTK474	1	72	sigmoid	sigmoid	BT549 ZSTK474 0 1 72	8	1.861	0.58	0.213	0.256	0.583	-0.00205	0.771	0.992	5.43e-07	NA	1.12	0.394	0.788	0.428	0.261	0.767	0.989	1.49e-06	NA
HCC38	ZSTK474	1	72	sigmoid	sigmoid	HCC38 ZSTK474 0 1 72	8	1.742	2.47	0.456	0.132	1.34	0.202	0.843	0.991	7.12e-07	NA	9.02	0.575	0.893	1.0	0.426	0.869	0.99	1.01e-06	NA

|<
<<
Previous
Page 17 of 18
Next
>>
>
401 to 425 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)